Photo: investing.com
FDA approves Teva's UZEDY for bipolar I disorder maintenance By Investing.com
The FDA has approved Teva Pharmaceuticals UZEDY, an injection (medicine) containing risperidone, for maintaining treatment of bipolar I disorder, marking a significant advancement in mental health therapies.
- Teva Pharmaceuticals and MedinCell announced that the Food and Drug Administration has approved UZEDY, a risperidone extended-release injectable suspension for adults with bipolar I disorder.
- UZEDY is intended for maintenance therapy and can be used in combination therapy with other medications such as lithium or valproate.
- The injection (medicine) is designed for subcutaneous tissue administration, providing a long-lasting treatment option for managing bipolar I disorder.
Why It Matters
This approval highlights ongoing advancements in psychiatric treatment options, offering patients with bipolar I disorder more effective management strategies. The introduction of UZEDY could improve adherence to treatment and overall patient outcomes.